Contract Research Services

Debate Over New Cancer Therapies

April 06, 2017

FDA is in the center of the debate over developing and pricing new cancer therapies.

Bristol-Myers Squibb Announces US Investments and Closures

December 14, 2016

BMS changes its US geographic footprint with R&D investments and closures.

Novartis, Kite Release Positive CAR-T Data

December 08, 2016

At the American Society of Hematology Annual Meeting, Novartis and Kite Pharma both released results from early-phase clinical trials with CAR-T therapies.

Catalent Expands Singapore Clinical Trials Hub

February 02, 2016

Catalent plans a $4.6 million investment to expand secondary packaging and storage in Asia.

The Impact of SEND on the Pharmaceutical Industry

February 01, 2016

Steven Denham, director of biostatistics at MPI Research, discusses the impact the Standard for Exchange of Nonclinical Data may have on the pharmaceutical industry.

Under New Ownership: Consolidation Reshapes Contract Services Market

February 01, 2016

Mergers and acquisitions have changed the shape of the contract services market as big players seek to build full-service capabilities.

Preventing Phase III Failures

February 01, 2016

Only half of new drugs make it past Phase III. Adopting best practices and collaborating more closely with contract research organizations can help ensure success.

AstraZeneca and the University of Manchester Team Up on Bioinformatics Venture

September 08, 2015

The partners will collaborate on a project to capture and integrate clinical trial data metrics on investigational cancer medications.

EMA Upholds GVK Biosciences Suspension Recommendation

May 26, 2015

PTSM: Pharmaceutical Technology Sourcing and Management

EMA confirms its recommendation to suspend medicines approved based on GVK Biosciences studies.

Positive Phase III Results Ends Pfizer’s Ibrance Trial Early

April 15, 2015

Pfizer announces that its Phase III trial for Ibrance met its primary endpoint and was ended early due to efficacy based on an assessment by an independent Data Monitoring Committee.